Stock ORTINLAB ORTIN LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ortin Laboratories Limited

Equities

ORTINLAB

INE749B01020

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:51 2024-05-31 am EDT 		5-day change 1st Jan Change
17 INR -2.47% Intraday chart for Ortin Laboratories Limited -7.36% -26.15%
Feb. 17 Ortin Laboratories Limited Announces Board Appointments CI
Feb. 13 Ortin Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Valuation

Fiscal Period: Marzo 2018 2019 2020 2021 2022 2023
Capitalization 1 304.1 238.2 123 262.2 183.8 141.4
Enterprise Value (EV) 1 497.5 411.5 328.8 329.9 240.3 203.7
P/E ratio 44.9 x 18.6 x -21.8 x 27.8 x -46.1 x -145 x
Yield - - - - - -
Capitalization / Revenue 0.38 x 0.14 x 0.06 x 3.19 x 2.23 x 2.35 x
EV / Revenue 0.62 x 0.25 x 0.17 x 4.01 x 2.92 x 3.38 x
EV / EBITDA 9.21 x 6.16 x 5.76 x 25.5 x 38.9 x 39.1 x
EV / FCF -29.8 x 17 x 18.6 x 1.88 x 15.7 x -36.8 x
FCF Yield -3.35% 5.89% 5.38% 53.2% 6.37% -2.72%
Price to Book 1.26 x 0.95 x 0.52 x 2.31 x 1.68 x 1.3 x
Nbr of stocks (in thousands) 8,131 8,131 8,131 8,131 8,131 8,131
Reference price 2 37.40 29.29 15.12 32.25 22.60 17.39
Announcement Date 10/17/18 9/6/19 12/7/20 12/3/21 9/8/22 9/8/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Marzo 2018 2019 2020 2021 2022 2023
Net sales 1 797.1 1,678 1,974 82.17 82.31 60.2
EBITDA 1 54.01 66.8 57.1 12.95 6.172 5.213
EBIT 1 37.16 49.27 37.55 10.1 3.235 2.712
Operating Margin 4.66% 2.94% 1.9% 12.29% 3.93% 4.5%
Earnings before Tax (EBT) 1 6.803 18.38 7.187 1.365 -4.564 -1.099
Net income 1 6.792 12.8 -5.638 9.455 -3.987 -0.936
Net margin 0.85% 0.76% -0.29% 11.51% -4.84% -1.55%
EPS 2 0.8333 1.574 -0.6934 1.160 -0.4900 -0.1200
Free Cash Flow 1 -16.68 24.22 17.68 175.6 15.31 -5.54
FCF margin -2.09% 1.44% 0.9% 213.71% 18.6% -9.2%
FCF Conversion (EBITDA) - 36.26% 30.96% 1,355.77% 248.01% -
FCF Conversion (Net income) - 189.25% - 1,857.45% - -
Dividend per Share - - - - - -
Announcement Date 10/17/18 9/6/19 12/7/20 12/3/21 9/8/22 9/8/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 193 173 206 67.7 56.5 62.3
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 3.581 x 2.594 x 3.605 x 5.223 x 9.158 x 11.94 x
Free Cash Flow 1 -16.7 24.2 17.7 176 15.3 -5.54
ROE (net income / shareholders' equity) 2.86% 5.21% -2.31% 5.38% -3.57% -0.86%
ROA (Net income/ Total Assets) 3.44% 3.45% 2.12% 0.92% 0.96% 0.81%
Assets 1 197.7 371.5 -266.2 1,032 -413.9 -115.7
Book Value Per Share 2 29.60 30.90 29.30 14.00 13.50 13.40
Cash Flow per Share 2 2.080 2.640 1.170 0.2200 0.6000 0.2700
Capex 1 12.4 31.4 31.2 - 1.25 -
Capex / Sales 1.56% 1.87% 1.58% - 1.52% -
Announcement Date 10/17/18 9/6/19 12/7/20 12/3/21 9/8/22 9/8/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ORTIN LABORATORIES LIMITED Stock Ortin Laboratories Limited
-26.15% 1.66M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ORTINLAB Stock
  4. Financials Ortin Laboratories Limited